53 results on '"Nutt D"'
Search Results
2. Psilocybin as a treatment for anorexia nervosa: 6-week and 3-month follow-up results
3. Validation of novel fMRI paradigms in gambling disorder
4. Functional aspect of brain PET measures of serotonin examined in depression; relationships with psychometric measures of mood, wellbeing, and connectedness
5. P.0885 The effect of psilocybin therapy for depression on low-frequency brain activity in response to music
6. P.0586 Effects of cannabidiol (CBD) alone and combined with Δ9-tetrahydrocannabinol (THC) on functional connectivity of the pain-matrix
7. P.3.03 A double-blind, placebo-controlled, parallel group study of the effect of Org 25935 on cognitive performance
8. P.3.07 Sleep changes during deep brain stimulation for treatment resistant depression: preliminary findings from a case study
9. P.1.i.042 - A multicenter positron emission tomography study of GABA receptor availability in adults with autism
10. P.4.012 - Cannabis increases wanting but not liking of music and dampens its rewarding effects on the brain
11. P.3.011 - Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery
12. P.6.b.006 - Alcohol dependent patients have blunted endogenous opioid release measured using [11C]carfentanil PET and dexamphetamine challenge
13. S.23.02 - Effects of ecstasy on autobiographical memories: implications for MDMA assisted psychotherapy
14. S.23.01 - Recent insights into the psychopharmacology of MDMA
15. S.12.07 - Effects of LSD and music on brain activity
16. NS.01.04 - The addiction perspective in NbN
17. P.3.039 Effects of LSD and music on brain activity
18. P.6.b.005 An fMRI study of nalmefene on alcohol effects in reward anticipation in alcohol dependence
19. S.25.02 Effects of MDMA on self-referent encoding and personal memories: implications for its use in PTSD
20. S.21.02 How to rescue CNS active drugs which fail in one indication: experience from the ECNP Medicines Chest Initiative
21. 5HT2a Receptors – a New Target for Depression?
22. C.01.01 Debate – cognitive dysfunction in depression: reality or mirage?
23. P.6.f.002 Endogenous opioid release in pathological gamblers after an oral amphetamine challenge: a [11C]carfentanil PET study
24. P.2.a.021 Genome-wide association study of antidepressant-induced sexual dysfunction in depressed males
25. P.3.008 Endogenous opioid release in pathological gamblers after an oral amphetamine challenge: a [C]carfentanil PET study
26. EPA-0255 – Clinical relevance of as-needed treatment with nalmefene in alcohol dependent patients
27. P.6.b.007 Clinical relevance of nalmefene in the treatment of alcohol dependence: subgroup analysis of patients with high drinking risk level
28. Are baseline physical symptoms characteristic of severe depression or a poor prognostic factor? Secondary analysis of the GenPod trial
29. JS01-01 - New classification of psychiatric medications: report of work in progress
30. P.6.c.009 Comparison of a benzodiazepine and alcohol challenge in opioid dependent human participants
31. P.1.e.017 The functional brain correlates of the psychedelic state: an arterial spin labelling study with psilocybin
32. E.06.01 Setting the stage – Antidepressants
33. C.04.01 Treatments for generalised anxiety disorder: mechanism of action and clinical effect
34. P.4.b.012 Acute anxiolytic drug treatment has no effect on the instrumental successive negative contrast effect using a modified forced choice serial reaction time task
35. S03-01 Introducing the pharmacology behind treatments to understand treatment challenges
36. E.01.02 Clinical aspects of GABA
37. S.17.03 Do changes in 5HT function underlie CBT efficacy in panic disorder?
38. S.1.02 Antidepressant pharmacotherapy – 2009 and beyond
39. Rapid onset anxiolytic efficacy after a single dose of Pregabalin: Dou-ble-blind, placebo-controlled evaluation using a dental anxiety model
40. P.8.a.026 Pharmacokinetics of (S)-zopiclone and (S)-desmethylzopiclone following dosing with zopiclone and eszopiclone
41. P.2.c.012 Serotonin transporter promoter polymorphism does not influence treatment response to escitalopram in depression
42. P.2.c.022 A systematic review of antidepressant induced jitteriness/anxiety syndrome
43. S.11.02 Validation of CO2 stress test in humans
44. C.20.03 Evolving therapy for managing depression: a brief look into the future
45. E.05.02 Assessing the noradrenalin system in humans
46. 5-HT1A receptor binding in panic disorder; comparison with depressive disorder and healthy volunteers using PET and [11C]WAY-100635
47. ECNP position paper on social phobia proceedings from an ECNP workshop in Jerusalem, October 1994
48. Chapter 5 - The MOC Counter: A Pharmacological Tool for the in VivoMeasurement of Ligand Occupancy Indices in the Human Brain
49. S-5-3 - Peripheral and endocrine measures of ECT'S effects: Relation to side effects and outcome
50. 588 The effects of caffeine and clonidine on eye movements
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.